A reader — I’ll name him Jack — not too long ago requested my ideas on his plans to pursue therapy with lecanemab for his gentle cognitive impairment brought on by Alzheimer’s illness. So we arrange a name to debate what it’s wish to dwell beset by the specter of Alzheimer’s illness, but in addition the promise of a therapy to gradual it.
Jack’s account of his neurologist’s workup and the various steps from prognosis to anti-amyloid remedy appeared so as. As we explored the main points, nonetheless, one thing felt out of order. The issue wasn’t what I used to be listening to; it was what I wasn’t listening to.
A vital character was lacking.
Proceed to STAT+ to learn the complete story…
